Skip to main content

System Messages

  • strict warning: Non-static method view::load() should not be called statically in /home1/finfacts/public_html/sites/all/modules/views/views.module on line 879.
  • strict warning: Declaration of views_handler_argument::init() should be compatible with views_handler::init(&$view, $options) in /home1/finfacts/public_html/sites/all/modules/views/handlers/views_handler_argument.inc on line 745.
  • strict warning: Declaration of views_handler_filter::options_validate() should be compatible with views_handler::options_validate($form, &$form_state) in /home1/finfacts/public_html/sites/all/modules/views/handlers/views_handler_filter.inc on line 589.
  • strict warning: Declaration of views_handler_filter::options_submit() should be compatible with views_handler::options_submit($form, &$form_state) in /home1/finfacts/public_html/sites/all/modules/views/handlers/views_handler_filter.inc on line 589.
  • strict warning: Declaration of views_handler_filter_node_status::operator_form() should be compatible with views_handler_filter::operator_form(&$form, &$form_state) in /home1/finfacts/public_html/sites/all/modules/views/modules/node/views_handler_filter_node_status.inc on line 14.
  • strict warning: Declaration of date_api_filter_handler::value_validate() should be compatible with views_handler_filter::value_validate($form, &$form_state) in /home1/finfacts/public_html/sites/all/modules/date/includes/date_api_filter_handler.inc on line 578.
  • strict warning: Non-static method view::load() should not be called statically in /home1/finfacts/public_html/sites/all/modules/views/views.module on line 879.
  • strict warning: Declaration of uc_product_handler_field_price::options() should be compatible with views_object::options() in /home1/finfacts/public_html/sites/all/modules/ubercart/uc_product/views/uc_product_handler_field_price.inc on line 94.
  • strict warning: Declaration of uc_product_handler_field_weight::options() should be compatible with views_object::options() in /home1/finfacts/public_html/sites/all/modules/ubercart/uc_product/views/uc_product_handler_field_weight.inc on line 61.
  • strict warning: Declaration of views_handler_field_user::init() should be compatible with views_handler_field::init(&$view, $options) in /home1/finfacts/public_html/sites/all/modules/views/modules/user/views_handler_field_user.inc on line 48.
  • strict warning: Declaration of semanticviews_plugin_style_default::options() should be compatible with views_object::options() in /home1/finfacts/public_html/sites/all/modules/semanticviews/semanticviews_plugin_style_default.inc on line 232.
  • strict warning: Declaration of views_plugin_row::options_validate() should be compatible with views_plugin::options_validate(&$form, &$form_state) in /home1/finfacts/public_html/sites/all/modules/views/plugins/views_plugin_row.inc on line 135.
  • strict warning: Declaration of views_plugin_row::options_submit() should be compatible with views_plugin::options_submit(&$form, &$form_state) in /home1/finfacts/public_html/sites/all/modules/views/plugins/views_plugin_row.inc on line 135.
  • strict warning: Non-static method view::load() should not be called statically in /home1/finfacts/public_html/sites/all/modules/views/views.module on line 879.
  • warning: Creating default object from empty value in /home1/finfacts/public_html/sites/all/modules/views/includes/handlers.inc on line 653.
  • strict warning: Declaration of views_plugin_style_default::options() should be compatible with views_object::options() in /home1/finfacts/public_html/sites/all/modules/views/plugins/views_plugin_style_default.inc on line 25.
  • strict warning: Non-static method view::load() should not be called statically in /home1/finfacts/public_html/sites/all/modules/views/views.module on line 879.
  • strict warning: Non-static method view::load() should not be called statically in /home1/finfacts/public_html/sites/all/modules/views/views.module on line 879.
Key Company News

Key Company News

(July 2013) The British manager of GlaxoSmithKline (GSK) China is reported to have fled the country and four senior executives from the British pharmaceutical giant and Europe's biggest drugs group, are being held by Chinese police on suspicion of having committed what the authorities term serious economic crimes. Novartis, the Swiss pharmaceutical giant has admitted this month that there was an undisclosed conflict of interest in a study of one of its drugs carried out at a Japanese university. Last April, the United States government announced its second civil fraud lawsuit against Novartis in four days, accusing a unit of the Swiss pharmaceuticals company of paying multi-million-dollar kickbacks to doctors in exchange for prescribing its drugs. Meanwhile, four pharmaceutical companies paid more than half of the $19.8bn in civil and criminal settlements over 20 years for improper billings to federal and state governments, according to a Dec 2010 report by Public Citizen’s Health Research Group. Four drug makers, GSK, Pfizer, Eli Lilly and Schering-Plough, accounted for $10.5bn of that amount, the report said.
(July 2013) Samsung is Asia's top brand for the second consecutive year and other brands to appear in the top five are Apple, Sony, Nestlé, and Panasonic, respectively.
(July 2013) The latest data shows that US S&P 500 companies added $30.1bn more in cash and short-term investments to their cash hoards in the first quarter of 2013, pushing up the total to $1.29tn. However, data also shows that investors punish high capital expenditures relative to sales, suggesting that the safety of large cash hoards, even at continuing low interest rates, are likely to remain a priority for companies in coming years.
(July 2013) IBM, the US technology giant, is cutting jobs in China after a disappointing decline in earnings. Meanwhile, US businessman Chip Starnes has been freed after being detained by workers in his factory in China for nearly a week over a dispute.
(July 2013) Using the same measure of options-realised CEO pay, the US CEO-to-worker compensation ratio was 20.1-to-1 in 1965 and 29.0-to-1 in 1978, grew to 122.6-to-1 in 1995, peaked at 383.4-to-1 in 2000, and was 272.9-to-1 in 2012, far higher than it was in the 1960s, 1970s, 1980s, or 1990s.
(June 2013) China's public subsidies, which have encouraged overcapacity in several sectors, have got attention in recent times as the government seeks to rebalance the economy towards the consumer sector. New data shows that companies listed on China's stock exchanges received ¥85.68bn yuan ($13.83bn) in government subsidies last year, up 23% from a year earlier, while corporate profits rose less than 1%. The subsidies were equivalent to more than 4% of the companies' total profits last year, up from around 3% between 2009 and 2011.
(June 2013) In a decision that is a setback for the pharmaceutical industry, the US Supreme Court has ruled that antitrust regulators should be able to challenge the arrangements that allow drug makers to delay the sale of a generic drug. In deals known as “reverse payments” or “pay for delay,” brand-name drug makers facing a patent challenge from generic competitors pay them to temporarily stay out of the market. Last year, there were 40 patent-dispute settlements between brand-name and generic drug makers involving a payment to the generic firm and restricted sale of a generic medicine, according to the US Federal Trade Commission (FTC.) The agreements related to 31 brand name drugs with yearly US sales of more than $8.3bn, the agency said.
(June 2013) Bloomberg says Chinese consumers spend about $183bn on pork a year, favouring pig head, feet and offal that aren’t popular on US menus. The nation’s farms are mostly small, which combined produce about five times more pig meat than the US China’s food industry had been wracked by scandals ranging from tainted milk to the illegal dumping of hogs in rivers. Last month, Smithfield Foods, one of the biggest pork producers in the US, agreed to be bought by China's Shuanghui International Holdings Ltd. The deal, which still faces a federal regulatory review and Smithfield shareholder approval, is the largest takeover of a US company by a Chinese firm, valued at about $7.1bn, including debt.
(June 2013) Novo Nordisk, the Danish pharmaceutical giant, dates from the 1920s and had its genesis in two small Danish companies Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium founded in 1923 and 1925, respectively. The companies started the production of the revolutionary new drug insulin that had just been discovered by two Canadian scientists. Today Novo Nordisk, the world's biggest maker of insulin, has 35,000 employees across the globe, including some 15,000 in Denmark, and has been slapped with a 5.5bn Danish crown ($1bn) tax demand involving the use of Switzerland for tax avoidance.
(May 2013) Merck's Januvia blockbuster diabetes drug, which made revenues of $4bn in 2012 and similar drugs for Type 2 diabetes, that make in total $9bn, are under scrutiny because of studies linking them with pancreatic cancer. Meanwhile, the top-selling class of blood-pressure drugs is under attack from an unusual source: a senior regulator at the Food and Drug Administration. Bucking his bosses, Thomas A. Marciniak is seeking stronger warnings about the drugs known as angiotensin receptor blockers, or ARBs, according to internal documents reviewed by The Wall Street Journal.